SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer
AuthorsHolyoake, D. L. P.
Hawkins, M. A.
AffiliationNorfolk and Norwich University Hospitals NHS Foundation Trust, United Kingdom.
MetadataShow full item record
AbstractBackground and purpose: Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk. Materials and methods: We conducted a prospective multicentre phase-1 rolling-six dose-escalation study. BRPC patients received pre-operative SBRT, with one dose to the primary tumour and an integrated boost to the region where tumour was in contact with vasculature. Four dose-levels were proposed, with starting dose 30 Gy to primary PTV and 45 Gy to boost volume (PTV_R), in five daily fractions. Primary endpoint was maximum tolerated dose (MTD), defined as highest dose where zero of three or one of six patients experienced dose-limiting toxicity (DLT). Results: Twelve patients were registered, eleven received SBRT. Radiotherapy was well tolerated with all treatment completed as scheduled. Dose was escalated one level up from starting dose without encountering any DLT (prescribed 32.5 Gy PTV, 47.5 Gy PTV_R). Nine serious adverse reactions or events occurred (seven CTCAE Grade 3, two Grade 4). Two patients went on to have surgical resection. Median overall survival for SBRT patients was 8.1 months. The study closed early when it was unable to recruit to schedule. Conclusion: Toxicity of SBRT was low for the two dose-levels that were tested, but MTD was not established. Few patients subsequently underwent resection of pancreatic tumour after SBRT, and it is difficult to draw conclusions regarding the safety or toxicity of these therapies in combination.
CitationHolyoake DLP, Robinson M, Silva M, Grose D, McIntosh D, Sebag-Montefiore D, et al. SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. Radiother Oncol. 2020;155:278-84.
JournalRadiotherapy and Oncology
- A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
- Authors: Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA
- Issue date: 2016 Sep 13
- A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
- Authors: Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF
- Issue date: 2016 Oct 1
- Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial.
- Authors: Deodato F, Macchia G, Cilla S, Ianiro A, Sallustio G, Cammelli S, Buwenge M, Mattiucci GC, Valentini V, Morganti AG
- Issue date: 2019 Feb
- Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
- Authors: Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, Birnbaum A, Brown University Oncology Research Group., Wazer DE, DiPetrillo T
- Issue date: 2016 Dec 1
- Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
- Authors: Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R
- Issue date: 2013 Jul 1